ALCHEMAB THERAPEUTICS, CSO

Jane is Chief Scientific Officer at Alchemab Therapeutics, which focusses on identifying self-protective antibodies as therapies for neurodegeneration and oncology. She was an early employee of Cambridge Antibody Technology, which became MedImmune, the biologics arm of AstraZeneca, where she contributed to the development of phage display technology, authored many key publications and patents, and contributed to the discovery and development of eight marketed drugs. She is passionate about the development of the biotechnology sector and served as Chair of the UK BioIndustry Association (BIA) from 2015-2019.

She is also the Chair of Mogrify, a Cambridge-based cell-therapy company, a founder of RQ Bio a UK-based infectious disease company, and has been a Director of Cambridge Enterprise, and of Babraham Research Campus. In 2019 she was awarded an OBE for services to drug discovery, development and biotechnology, and in the same year the Scrip Lifetime Achievement Award for contribution to the pharma industry.

In 2023 she was awarded the BIA life time achievement award, recognising her sustained contribution to biologics drug development.